HCM vs ZLAB

For growth investors, Zai Lab Limited (ZLAB) is the stronger pick with 15.

3% revenue growth year-over-year, versus -24. 8% for HUTCHMED (China) Limited (HCM). HUTCHMED (China) Limited (HCM) offers the better valuation at 61. 0x trailing P/E (42. 0x forward), making it the more compelling value choice. Analysts rate HUTCHMED (China) Limited (HCM) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, HUTCHMED (China) Limited (HCM) delivered a total return of -50.

4%, compared to -86. 5% for Zai Lab Limited (ZLAB). Over 10 years, the gap is even starker: HCM returned -2. 7% versus ZLAB's -24. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), HUTCHMED (China) Limited (HCM) is the lower-risk stock at 0.

66β versus Zai Lab Limited's 1. 21β — meaning ZLAB is approximately 83% more volatile than HCM relative to the S&P 500. On balance sheet safety, HUTCHMED (China) Limited (HCM) carries a lower debt/equity ratio of 12% versus 31% for Zai Lab Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zai Lab Limited (ZLAB) is pulling ahead at 15.

3% versus -24. 8% for HUTCHMED (China) Limited (HCM). On earnings-per-share growth, the picture is similar: Zai Lab Limited grew EPS 38. 5% year-over-year, compared to -63. 3% for HUTCHMED (China) Limited. Over a 3-year CAGR, ZLAB leads at 28. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

HUTCHMED (China) Limited (HCM) is the more profitable company, earning 6.

0% net margin versus -38. 1% for Zai Lab Limited — meaning it keeps 6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCM leads at -6. 9% versus -49. 9% for ZLAB. At the gross margin level — before operating expenses — ZLAB leads at 58. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ZLAB: 66.

6% to $35. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, HUTCHMED (China) Limited (HCM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

66)). Both have compounded well over 10 years (HCM: -2. 7%, ZLAB: -24. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HCM is a small-cap quality compounder stock; ZLAB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.